During a Q2 earnings call, the firm discussed progress on an FGFR2b antibody, a subcutaneous version of Blincyto, and ...

Patients must express PPARG in at least 60 percent of tumor cells to enroll in the trial and receive the investigational drug.

The operating efficiency effort includes "employment-related and other operating expense reductions in early research," the firm said.